NCT05572255View on ClinicalTrials.gov

A Randomized, Open-label, Three-way Crossover Study to Evaluate the Relative Bioavailability of 200 Mg Cenobamate Administered Orally

PHASE1CompletedINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

September 27, 2022

Primary Completion Date

January 28, 2023

Study Completion Date

January 28, 2023

Conditions

Healthy Volunteers

Interventions

DRUG

Cenobamate

200 mg Cenobamate Tablet

Trial Locations (1)

78217

Worldwide Clinical Trials, San Antonio

All Listed Sponsors

lead

SK Life Science, Inc.

INDUSTRY